Procyon Advisors LLC Sells 134 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Procyon Advisors LLC trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,410 shares of the company’s stock after selling 134 shares during the period. Procyon Advisors LLC’s holdings in IDEXX Laboratories were worth $583,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. RDA Financial Network raised its holdings in IDEXX Laboratories by 47.1% during the fourth quarter. RDA Financial Network now owns 2,605 shares of the company’s stock valued at $1,077,000 after acquiring an additional 834 shares during the period. Ritholtz Wealth Management boosted its stake in IDEXX Laboratories by 43.8% in the 4th quarter. Ritholtz Wealth Management now owns 956 shares of the company’s stock worth $395,000 after purchasing an additional 291 shares during the period. Gateway Investment Advisers LLC grew its holdings in IDEXX Laboratories by 11.5% during the 4th quarter. Gateway Investment Advisers LLC now owns 12,349 shares of the company’s stock valued at $5,106,000 after buying an additional 1,274 shares in the last quarter. Outlook Wealth Advisors LLC raised its position in shares of IDEXX Laboratories by 20.5% during the fourth quarter. Outlook Wealth Advisors LLC now owns 852 shares of the company’s stock valued at $352,000 after buying an additional 145 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after buying an additional 316,048 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.18% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the topic of a number of research reports. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Barclays decreased their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Piper Sandler reissued a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $523.86.

IDEXX Laboratories Stock Down 2.2 %

Shares of IDXX opened at $419.26 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average of $423.60 and a 200 day moving average of $458.13. The company has a market cap of $34.33 billion, a PE ratio of 40.43, a P/E/G ratio of 3.52 and a beta of 1.36. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business’s revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the business earned $2.53 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.